Thyroid peroxidase and gatectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation

被引:29
作者
Savin, Svettana [1 ]
Cvejic, Dubravka [1 ]
Isic, Tijana [1 ]
Paunovic, Ivan [2 ]
Tatic, Svetistav [3 ]
Havelka, Marija [3 ]
机构
[1] Univ Belgrade, Inst Applicat Nucl Energy INEP, Zemun Belgrade 11080, Serbia
[2] Clin Ctr Serbia, Inst Endocrinol Diabet & Dis Metab, Ctr Endocrine Surg, Belgrade 11000, Serbia
[3] Univ Belgrade, Fac Med, Inst Pathol, Belgrade 11000, Serbia
关键词
Thyroid peroxidase; Galectin-3; Thyroid carcinoma; Immunohistochemistry; Clinicopathologic;
D O I
10.1016/j.humpath.2008.04.006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Thyroperoxidase and galectin-3 have been reported as useful immunohistochemical markers of thyroid malignancy. In this study, we evaluated the relationship between immunohistochemical staining results for these markers and clinicopathologic features of patients with differentiated thyroid cancer. A total of 193 archival thyroid samples including 28 follicular adenomas, 18 follicular carcinomas, and 147 papillary carcinomas with 114 adjacent thyroid tissues were analyzed by immunohistochemistry. Thyroperoxidase was underexpressed (< 50% stained thyrocytes), and galectin-3 was expressed (> 5% stained thyrocytes) in most carcinomas. The sensitivity for diagnosis of differentiated thyroid carcinoma was 86.1% for thyroperoxidase and 82.4% for galectin-3, whereas the combination of both markers increased the sensitivity up to 94.5%. Thus, the combination of thyroperoxidase and galectin-3 immunohistochemistry may help to ascertain the malignant nature of the lesion. Furthermore, tumor size, nodal involvement, extrathyroidal invasion, and high tumor-node-metastasis stage in patients with papillary carcinoma were related to thyroperoxidase absence and high galectin-3 expression in most cases (P <.05). In patients with follicular carcinoma, the extent of invasiveness was associated with galectin-3 positivity. Thus, expression of these markers is related to more or less aggressive biological behavior of differentiated thyroid carcinomas. Although thyroperoxidase presence may indicate favorable prognosis of papillary cancer, expression of galectin-3 illustrates the potential importance of this protein in the pathogenesis and/or progression of differentiated thyroid carcinomas. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1656 / 1663
页数:8
相关论文
共 39 条
[21]  
2-1
[22]   Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma [J].
Ito, Y ;
Yoshida, H ;
Tomoda, C ;
Miya, A ;
Kobayashi, K ;
Matsuzuka, F ;
Yasuoka, H ;
Kakudo, K ;
Inohara, H ;
Kuma, K ;
Miyauchi, A .
PATHOLOGY, 2005, 37 (04) :296-298
[23]   Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation [J].
Kawachi, K ;
Matsushita, Y ;
Yonezawa, S ;
Nakano, S ;
Shirao, K ;
Natsugoe, S ;
Sueyoshi, K ;
Alkou, T ;
Sato, E .
HUMAN PATHOLOGY, 2000, 31 (04) :428-433
[24]  
Kholová I, 2003, ANTICANCER RES, V23, P871
[25]  
Krzeslak A, 2004, CELL MOL BIOL LETT, V9, P305
[26]   Thyroid peroxidase expression in diseased human thyroid glands [J].
Lima, MA ;
Gontijo, VA ;
Santos, MC ;
Schmitt, FCL .
ENDOCRINE PATHOLOGY, 1999, 10 (03) :223-228
[27]   Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma [J].
Lloyd, RV ;
Erickson, LA ;
Casey, MB ;
Lam, KY ;
Lohse, CM ;
Asa, SL ;
Chan, JKC ;
DeLellis, RA ;
Harach, R ;
Kakudo, K ;
LiVolsi, VA ;
Rosai, J ;
Sebo, TJ ;
Sobrinho-Simoes, M ;
Wenig, BM ;
Lae, ME .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (10) :1336-1340
[28]  
Orlandi F, 1998, CANCER RES, V58, P3015
[29]   Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors [J].
Prasad, ML ;
Pellegata, NS ;
Huang, Y ;
Nagaraja, HN ;
de la Chapelle, A ;
Kloos, RT .
MODERN PATHOLOGY, 2005, 18 (01) :48-57
[30]   Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunlohistochemical markers: a proposal for clinical application [J].
Saggiorato, E ;
De Pompa, R ;
Volante, M ;
Cappia, S ;
Arecco, F ;
Dei Tos, AP ;
Orlandi, F ;
Papotti, M .
ENDOCRINE-RELATED CANCER, 2005, 12 (02) :305-317